Overview

Apixaban for Extended Anticoagulation (APIDULCIS)

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients at high risk of recurrence (with altered D-dimer test), who had received anticoagulation (whatever the drug used) for 12-15 months after the first episode of thrombosis, will be treated with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.
Phase:
Phase 4
Details
Lead Sponsor:
Arianna Anticoagulazione Foundation
Treatments:
Apixaban
Fibrin fragment D